{
  "meta": {
    "title": "Neet_Pg_2025",
    "url": "https://brainandscalpel.vercel.app/neet-pg-2025-b95ac772.html",
    "scrapedAt": "2025-11-30T07:36:17.242Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Esmolol</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Phenoxybenzamine</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Nifedipine</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Clonidine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 38-year-old female presents with a pounding headache, palpitations, and sweating for 2 months. Each episode lasts for 20 minutes and is triggered by stress or physical exertion. Her pulse is 112/min, BP is 180/100 mm Hg, and urine shows elevated VMA and normetanephrines. MRI reveals a right adrenal mass. Which drug can be used both pre- and intra-operatively?</span></p>",
      "unique_key": "DT1325282",
      "question_audio": null,
      "question_video": null,
      "map_id": 1325282,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The given clinical features of <strong>headache</strong>, palpitations, sweating, hypertension, elevated catecholamine metabolites, and adrenal mass are suggestive of <strong>pheochromocytoma,</strong> and among the given options, the drug that can be used both pre- and intra-operatively is <strong>phenoxybenzamine</strong>.</p>\n<ul>\n<li><strong>Pheochromocytomas</strong> are adrenal tumours that release large amounts of catecholamines, leading to episodes of severe, sometimes life-threatening hypertension.</li>\n<li>Phenoxybenzamine, an <strong>irreversible nonselective &alpha;-adrenergic antagonist,</strong> reduces peripheral resistance by blocking &alpha;-receptors in blood vessels.</li>\n<li>This action helps blunt the hypertensive surges and cardiovascular complications caused by sudden catecholamine release.</li>\n<li>By stabilising blood pressure and reducing risks such as plasma volume contraction and myocardial injury, it prepares patients safely for surgery.</li>\n<li>Treatment is started <strong>1-3 weeks before the operation</strong>, with the dose gradually titrated until the desired blood pressure control is achieved.</li>\n<li>For inoperable or malignant cases, long-term therapy with phenoxybenzamine may still be required.</li>\n<li>The properties of phenoxybenzamine are summarised in the table below.</li>\n</ul>\n<p><img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250910c1666c93-bc78-48a5-a9bb-600a36b8dd14.png\" alt=\"\" /></p>\n<ul>\n<li><strong>&alpha;-adrenergic receptors</strong> regulate many vital actions of catecholamines.</li>\n</ul>\n<img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250910806d75c3-0aed-4e90-aed5-53fde4a1a192.png\" alt=\"\" /></li>\n<ul>\n<li>Both receptor types also influence <strong>vascular tone </strong>in arteries and veins.\n<li>Clinically, the main observable effects of &alpha;-blockers are cardiovascular, depending on the patient's condition and the drug's <strong>selectivity</strong> for &alpha;<sub>1</sub> or &alpha;<sub>2</sub> receptors.</li>\n<li>Antagonists vary in chemical nature and receptor preference and are summarised in the flowchart below.</li>\n</ul>\n<p><img class=\"w-100\" style=\"height: auto; display: block; vertical-align: middle; border: 0;\" src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250910aa1b4f75-58f2-4afd-8d06-25bcd144c82f.png\" alt=\"\" /></p>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Esmolol (Option A): </strong>Beta-adrenergic blockers are also given in pheochromocytoma treatment, but only once an alpha-receptor antagonist has been administered first. Moreover, esmolol is a <strong>beta-1 selective blocker</strong>, which is quickly broken down by esterases in red blood cells and has a half-life of around <strong>8 minutes</strong>. Hence, not suitable for pre- and intra-op use for pheochromocytoma.</p>\n<p><strong>Nifedipine (Option C): </strong>Nifedipine is a dihydropyridine calcium channel blocker, and the extended-release version is used in the management of <strong>hypertension</strong> but is not commonly used for the management of pheochromocytoma.</p>\n<p><strong>Clonidine (Option D): </strong>A single dose of clonidine has been employed to help distinguish cases of hypertension in patients suspected of having pheochromocytoma. It is not useful for pre- and intraoperative management of pheochromocytoma.</p>",
      "correct_choice_id": 2,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">0</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">1</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">2</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">3</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In the given cardiac action potential graph, identify the phase where amiodarone acts.<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250925070cc09a-d26e-4f3b-bc02-1623afc4fe2a.png\"></span></p>",
      "unique_key": "DT1325286",
      "question_audio": null,
      "question_video": null,
      "map_id": 1325286,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation: </strong></p>\n<p><strong>Amiodarone </strong>is a <strong>class III anti-arrhythmic agents</strong>, which act on <strong>phase 3 </strong>of the cardiac action potential, which is the <strong>repolarisation phase</strong>.</p>\n<ul>\n<li>Amiodarone is a structural analogue of thyroid hormone with multiple electrophysiological effects.</li>\n<li>Blocks inactivated Na+ channels, decreases Ca&sup2;+ current, prolongs PR, QRS, and QT intervals, and <strong>delays repolarisation</strong> by blocking K+ channels. <strong>(Options A, B, and C ruled out)</strong></li>\n</ul>\n<p>The phases of the cardiac action potential are given below.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250910a385dd03-a683-4314-8ed8-e7a6ade6eb95.png\"><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250910a4508942-e1b7-48b9-9673-3071459397f4.png\">\n<p>Anti-arrhythmic drugs are classified as below.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509105d574101-e74d-4e50-81e6-e3d971751f79.png\">",
      "correct_choice_id": 14,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Oxidises uric acid</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Hydrolyses uric acid</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibits xanthine oxidase</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibits URAT-1 transporters in the kidney</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient with tumour lysis syndrome has elevated uric acid levels. What is the mechanism of action of pegloticase?</span></p>",
      "unique_key": "DT1325289",
      "question_audio": null,
      "question_video": null,
      "map_id": 1325289,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Pegloticase</strong> is a pegylated uricase that <strong>oxidises uric acid </strong>by converting it into allantoin.</p>\r\n<p>The properties of pegloticase are as below.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250910ec719dbb-255d-48b4-9f30-21e38addb406.png\">\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>Hydrolyses uric acid (Option B): </strong>Pegloticase oxidises uric acid into allantoin.</p>\r\n<p><strong>Inhibits xanthine oxidase (Option C): </strong>Describes the mechanism of allopurinol and febuxostat, not pegloticase.</p>\r\n<p><strong>Inhibits URAT-1 transporters in the kidney (Option D): </strong>Probenecid and lesinurad exert their therapeutic effects through this mechanism.</p>",
      "correct_choice_id": 21,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Isoniazid, levofloxacin, ethambutol, clarithromycin - QT prolongation</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Isoniazid, levofloxacin, ethambutol, pyrazonamide - hepatotoxicity</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Isoniazid, ethambutol, pyrazinamide - optic neuritis</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">BPaLM regimen - IRIS</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A female patient with HIV infection (CD4 count 150 cells/mm&sup3;) was newly diagnosed with rifampicin-resistant tuberculosis. What anti-tubercular treatment regimen should be initiated, and which HIV-related complication should you look out for?</span></p>",
      "unique_key": "DT1325293",
      "question_audio": null,
      "question_video": null,
      "map_id": 1325293,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>According to WHO guidelines, rifampicin-resistant or multidrug-resistant TB is treated with a 6-month all-oral regimen <strong>BPaLM</strong> (Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin).</p>\r\n<p><strong>WHO Recommendations on New, Shorter Oral Regimens (MDR/RR-TB)</strong></p>\r\n<p>WHO (2022) prioritised a 6-month all-oral regimen BPaLM (Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin) as the treatment of choice for <strong>MDR/RR-TB </strong>in eligible patients. <strong>(Options A, B, and C ruled out)</strong></p>\r\n<p><strong>Key Points:</strong></p>\r\n<p>All patients with MDR/RR-TB, including those resistant to fluoroquinolones, should receive effective oral regimens under programmatic conditions.</p>\r\n<p>The 6-month BPaLM regimen is recommended for patients <strong>&ge;14 years</strong> who have not had prior exposure to Bdq, Pa, and Lzd (beyond one month).</p>\r\n<p>In place of longer (9-18 months) regimens, BPaLM can be used programmatically.</p>\r\n<p>If BPaLM cannot be given, a<strong> 9-month all-oral Bdq regimen</strong> is suggested, including 2 months of Lzd (600 mg) as an alternative to 4 months of Eto.</p>\r\n<p>Inclusion Criteria for BPaLM regimen</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025091037482c49-fdfc-4c26-9537-361e3b617a5d.png\">\r\n<ul>\r\n<li><strong>Immune reconstitution inflammatory syndrome (IRIS)</strong>, also called TB immune reconstitution disease, refers to worsening clinical signs such as fever, lymph node enlargement, pulmonary infiltrates, or pleural effusion, along with laboratory or radiological evidence of TB progression.</li>\r\n<li>It appears in about 10% of <strong>HIV-positive TB patients</strong>, usually within 1-3 months of <strong>ART initiation</strong>. It occurs more often in individuals with severe immunosuppression and extrapulmonary TB.</li>\r\n<li>The proposed mechanism of IRIS involves an <strong>immune reaction</strong> triggered by antigens released when bacilli are destroyed during successful treatment, occurring alongside recovering immune function.</li>\r\n<li>When IRIS develops in relation to a known infection or tumour, it is termed <strong>paradoxical IRIS,</strong> whereas its occurrence due to a previously hidden condition is called <strong>unmasking IRIS.</strong></li>\r\n<li>The risk is greater when ART is initiated early and in those with <strong>very low baseline CD4+ counts</strong>. Death from IRIS is rare but may happen, particularly in patients with severe disease.</li>\r\n</ul>\r\n<p><strong>Reference: </strong><a href=\"https://tbcindia.mohfw.gov.in/wp-content/uploads/2025/01/National-Guidelines-for-Management-of-DR-TB_Final.pdf\" target=\"_blank\" >https://tbcindia.mohfw.gov.in/wp-content/uploads/2025/01/National-Guidelines-for-Management-of-DR-TB_Final.pdf</a></p>",
      "correct_choice_id": 34,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Pioglitazone</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Empagliflozin</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Glibenclamide</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Sitagliptin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs is most appropriate to be started in a diabetic patient with an HbA1c of 8.8 mmol/L with heart failure who is already on metformin and insulin glargine?</span></p>",
      "unique_key": "DT1325294",
      "question_audio": null,
      "question_video": null,
      "map_id": 1325294,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Empagliflozin </strong>is an <strong>SGLT2 Inhibitor</strong> that helps to control blood glucose and provides cardiovascular benefits, and is most appropriate to be started in this patient.</p>\r\n<p><strong>Mechanism:</strong></p>\r\n<ul>\r\n<li>SGLT2 inhibitors act on the sodium-glucose cotransporter 2 located in the <strong>proximal renal tubule</strong>, which normally reabsorbs about 80-90% of filtered glucose.</li>\r\n<li>By blocking this transporter, these drugs <strong>reduce glucose reabsorption</strong>, leading to urinary glucose loss and lowering blood glucose levels.</li>\r\n<li>Available drugs include <strong>canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin</strong>.</li>\r\n</ul>\r\n<p><strong>Cardiovascular Effects</strong></p>\r\n<ul>\r\n<li>All four reduced hospitalisation for heart failure, with <strong>dapagliflozin</strong> significantly lowering hospitalisation and cardiovascular death, even in non-diabetic patients.</li>\r\n<li><strong>Canagliflozin</strong> specifically reduced admissions for heart failure in diabetic nephropathy.</li>\r\n</ul>\r\n<p><strong>Renal Effects</strong></p>\r\n<ul>\r\n<li>Slows down the <strong>progression of kidney disease</strong> in trials, lowering albuminuria and improving outcomes in patients with reduced renal function.</li>\r\n<li>They are recommended early in diabetes management when nephropathy or cardiovascular disease is present.</li>\r\n</ul>\r\n<p><strong>Adverse Effects and Safety Concerns</strong></p>\r\n<ul>\r\n<li>Increased risk of <strong>urinary tract infections</strong> and <strong>genital mycotic infections</strong></li>\r\n<li>Osmotic diuresis can cause mild dehydration and hypotension, mainly in older patients.</li>\r\n<li>Reduced efficacy in advanced kidney disease (GFR &lt;60-30 mL/min).</li>\r\n</ul>\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>Pioglitazone (Option A): </strong>Belongs to the <strong>Thiazolidinediones (TZDs)</strong> group of drugs. Long-term clinical trial data have shown that use of these drugs can raise the risk of developing heart failure by as much as two times.</p>\r\n<p><strong>Glibenclamide( Option C): </strong>Despite ongoing debate regarding the cardiovascular safety of <strong>sulfonylureas</strong>, recent comparative clinical studies show that this drug class does not carry a higher risk of cardiovascular events than other widely used glucose-lowering medications. SGLT-2 inhibitors are better suited for the patient as they offer cardiovascular benefits.</p>\r\n<p><strong>Sitagliptin (Option D): </strong>Sitagliptin is a <strong>DPP-4 inhibitor.</strong> These drugs did not affect the rate of cardiovascular events in diabetic patients, but treatment with saxagliptin was linked to a higher likelihood of hospitalisation due to heart failure.</p>",
      "correct_choice_id": 42,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Aspirin</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Clopidogrel</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Warfarin</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">LMWH</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 32-year-old woman with a BMI of 38 kg/m&sup2; undergoes an elective lower segment cesarean section (LSCS) at 35 weeks due to preeclampsia. Which of the following is the most appropriate pharmacological method for DVT prophylaxis in this patient?</span></p>",
      "unique_key": "DT1325298",
      "question_audio": null,
      "question_video": null,
      "map_id": 1325298,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Low molecular weight heparin (LMWH) </strong>is the first-line pharmacological agent for <strong>DVT prophylaxis </strong>in a patient following a cesarean section with risk factors such as obesity.</p>\r\n<ul>\r\n<li>LMWH enhances the activity of <strong>antithrombin</strong>, leading to inhibition of <strong>factor Xa</strong> and, to a lesser extent, thrombin. This produces a predictable anticoagulant effect.</li>\r\n<li>Uses include prophylaxis and treatment of <strong>thromboembolic disorders</strong> such as deep vein thrombosis and <strong>pulmonary embolism,</strong> management of acute coronary syndromes, and prevention of clotting in high-risk patients like those undergoing surgery, pregnant women, and children.</li>\r\n<li><strong>Cesarean delivery</strong> significantly increases the risk of deep vein thrombosis (DVT) and pulmonary embolism compared to vaginal birth, making pulmonary embolism a major contributor to maternal mortality.</li>\r\n<li>The American College of Obstetricians and Gynaecologists (since 2011) recommends <strong>pneumatic compression devices </strong>before cesarean delivery for women not already on prophylaxis.</li>\r\n<li>For patients with additional thromboembolic risk factors, <strong>both compression devices and anticoagulants </strong>such as UFH or LMWH may be considered. <strong>(Options A, B, and C ruled out)</strong></li>\r\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509108dba1c2b-43ee-4a2c-b682-2e405c20a3e5.png\">",
      "correct_choice_id": 54,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased calcium excretion</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased calcium excretion</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Increased oxalate absorption</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Decreased citrate excretion</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the mechanism of renal calculi formation in a patient on Hydrochlorothiazide?</span></p>",
      "unique_key": "DT1325301",
      "question_audio": null,
      "question_video": null,
      "map_id": 1325301,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Hydrochlorothiazide</strong> leads to <strong>decreased citrate excretion</strong>, which is linked to r<strong>enal calculi formation</strong>.</p>\r\n<ul>\r\n<li><strong>Hypocitraturia </strong>refers to reduced citrate levels in the urine and represents a significant metabolic abnormality strongly linked to kidney stone formation.</li>\r\n<li>Citrate normally <strong>binds to calcium</strong>, preventing it from forming crystals and stones.</li>\r\n<li>Insufficient citrate <strong>increases calcium stone risk</strong>, making hypocitraturia one of the most common yet treatable causes of nephrolithiasis.</li>\r\n</ul>\r\n<p><strong>Etiology:</strong></p>\r\n<ul>\r\n<li>Citrate excretion depends on gastrointestinal alkali absorption. Low urinary citrate can result from <strong>high meat</strong> and sodium intake with poor fruit consumption, medications such as <strong>thiazides</strong>, ACE inhibitors, topiramate, and acetazolamide.</li>\r\n<li>Conditions like IBS, chronic diarrhoea, short bowel syndrome, and post-bariatric surgery are also implicated.</li>\r\n<li>Hormonal and metabolic factors also play a role: higher levels are seen in women, influenced by estrogens, vitamin D, and growth hormone, whereas testosterone, starvation, and acidosis reduce levels.</li>\r\n</ul>\r\n<p>Citrate prevents stone formation by multiple mechanisms:</p>\r\n<ol>\r\n<li>Binding calcium to reduce crystal availability.</li>\r\n<li>Directly inhibiting crystal growth and aggregation.</li>\r\n<li>Raising urinary pH, improving uric acid solubility.</li>\r\n<li>Limiting osteopontin and other stone matrix components.</li>\r\n<li>Reducing the stone-promoting effect of urinary proteins like Tamm-Horsfall protein.</li>\r\n<li>Increasing urine viscosity, which reduces crystal aggregation.</li>\r\n</ol>\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>Increased calcium excretion (Option A): </strong>Thiazide diuretics lead to decreased calcium excretion.</p>\r\n<p><strong>Decreased calcium excretion (Option B): </strong>Decreased calcium excretion is seen with thiazide use, which is beneficial in patients with <strong>osteopenia </strong>and <strong>hypercalciuria</strong>.</p>\r\n<p><strong>Increased oxalate absorption (Option C): </strong>Thiazide diuretics have no measurable effect on urinary oxalate excretion.</p>\r\n<p><strong>Reference: </strong><a href=\"https://www.ncbi.nlm.nih.gov/books/NBK564392/\" target=\"_blank\">https://www.ncbi.nlm.nih.gov/books/NBK564392/</a></p>\r\n<p>&nbsp;<a href=\"https://www.auajournals.org/doi/10.1097/01.ju.0000076371.92938.9b#:~:text=Conclusions%3A,be%20detected%20in%20clinical%20practice.\" target=\"_blank\">https://www.auajournals.org/doi/10.1097/01.ju.0000076371.92938.9b#:~:text=Conclusions%3A,be%20detected%20in%20clinical%20practice.</a></p>",
      "correct_choice_id": 64,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">10</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">14</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">4</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">20</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In the Pritchard regimen for the management of eclampsia, what is the loading dose of magnesium sulfate?</span></p>",
      "unique_key": "DT1325303",
      "question_audio": null,
      "question_video": null,
      "map_id": 1325303,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Loading dose of magnesium sulfate in the Pritchard regimen is: 4 grams IV + 10 grams IM, ie, a total of <strong>14 grams</strong>.</p>\r\n<p>The <strong>Pritchard regimen</strong> is a standard protocol for the treatment of <strong>eclampsia</strong> using <strong>magnesium sulfate</strong>.</p>\r\n<p><strong>Dosage:</strong></p>\r\n<ul>\r\n<li><strong>Loading dose:</strong>\r\n<ul>\r\n<li>4 g magnesium sulfate <strong>IV</strong> (20% solution) given slowly over 5 minutes.</li>\r\n<li>10 g magnesium sulfate <strong>IM</strong> (50% solution), 5 g into each buttock with 1 mL of 2% lignocaine to reduce pain. <strong>(Options A, C, and D Ruled out )</strong></li>\r\n</ul>\r\n</li>\r\n<li><strong>Maintenance dose:</strong>\r\n<ul>\r\n<li>5 g magnesium sulfate <strong>IM</strong> every 4 hours, alternately in each buttock, if the patient has:\r\n<ul>\r\n<li>Respiratory rate &gt; 12/min</li>\r\n<li>Urine output &gt; 100 mL in 4 hours</li>\r\n<li>Patellar reflex present</li>\r\n</ul>\r\n</li>\r\n</ul>\r\n</li>\r\n<li>It is continued for <strong>24 hours after the last seizure</strong> or <strong>24 hours after delivery</strong>, whichever is later.</li>\r\n</ul>\r\n<p><strong>Magnesium Sulfate Toxicity:</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250910f2809111-e24f-4195-960a-01ebfc449286.png\">",
      "correct_choice_id": 72,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">IV adenosine</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">IV esmolol</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Oral phenytoin</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Oral verapamil</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient is diagnosed with paroxysmal supraventricular tachycardia and requires prophylaxis for the same. Which of the following drugs is appropriate for this patient?</span></p>",
      "unique_key": "DT1325306",
      "question_audio": null,
      "question_video": null,
      "map_id": 1325306,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Among the given options, verapamil is appropriate for the prophylaxis of paroxysmal supraventricular tachycardia.</p>\r\n<p><strong>Verapamil</strong></p>\r\n<p><strong>Mechanism:</strong></p>\r\n<ul>\r\n<li>Blocks <strong>L-type Ca&sup2;&sup+; channels</strong> in the AV node.</li>\r\n<li>Slows AV nodal conduction and increases the refractory period.</li>\r\n<li>Interrupts the re-entry circuit commonly responsible for PSVT.</li>\r\n</ul>\r\n<p><strong>Use:</strong></p>\r\n<ul>\r\n<li>Effective in terminating <strong>AV nodal re-entrant tachycardia (AVNRT)</strong>, the most common form of PSVT.</li>\r\n<li>Given intravenously for acute termination and <strong>orally for prophylaxis</strong> of PSVT.</li>\r\n<li>Prophylaxis of migraine</li>\r\n<li>Improves left ventricular outflow obstruction in patients with<strong> hypertrophic obstructive cardiomyopathy</strong>.</li>\r\n</ul>\r\n<p><strong>Contraindications:</strong></p>\r\n<ul>\r\n<li>Avoid in <strong>WPW syndrome with atrial fibrillation</strong> (can worsen conduction via accessory pathway).</li>\r\n<li>Contraindicated in severe LV dysfunction, hypotension, or heart block.</li>\r\n</ul>\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>IV adenosine (Option A): </strong>It is used acutely to terminate PSVT but not for prophylaxis since it has a very short half-life of about 10 seconds.</p>\r\n<p><strong>IV esmolol (Option B): </strong>It is an ultra-short-acting beta-blocker, used acutely often in intraoperative or critical care settings, but it is not suitable for chronic prophylaxis.</p>\r\n<p><strong>Oral phenytoin (Option C): </strong>It is an anti-epileptic that may have anti-arrhythmic properties in digitalis toxicity, but it is not used in PSVT prophylaxis.</p>",
      "correct_choice_id": 84,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Naratriptan</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Propranolol</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Topiramate</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Ergotamine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A female diagnosed with migraine presents to the OPD and complains of 4-5 episodes per month, with each episode lasting 24-48 hours. She also experiences anxiety and palpitations. She experiences partial pain relief with OTC NSAIDs and was started on sumatriptan prophylaxis, but developed chest tightness and flushing. She has no history of cardiac illnesses, but there is a positive family history of coronary artery disease. Which of the following drugs can be used for prophylaxis in this patient?</span></p>",
      "unique_key": "DT1325307",
      "question_audio": null,
      "question_video": null,
      "map_id": 1325307,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p>Among the given options, <strong>propranolol</strong> is preferred in this patient for <strong>migraine prophylaxis</strong> since it will also alleviate anxiety and palpitations experienced by the patient.</p>\r\n<ul>\r\n<li>Patients who experience <strong>frequent migraine attacks</strong> (typically four or more per month), or whose attacks do not respond well to acute therapies, are candidates for preventive medications.</li>\r\n<li>These drugs often cause side effects, and dosing is challenging since the recommendations are based on studies for other conditions. Their exact mechanism is uncertain, but they likely alter brain sensitivity related to migraine.</li>\r\n<li>Some of the FDA-approved preventive options include <strong>propranolol,</strong> timolol, rimegepant, sodium valproate, <strong>topiramate</strong>, eptinezumab, and erenumab.</li>\r\n<li>Once migraines are controlled, treatment is usually continued for around six months, then tapered gradually.</li>\r\n<li>The introduction of monoclonal antibodies targeting CGRP receptors or peptides (erenumab, eptinezumab, fremanezumab, and galcanezumab) has notably advanced migraine prevention.</li>\r\n</ul>\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>Naratriptan (Option A): </strong>Triptans strongly bind to<strong> 5-HT1B and 5-HT1D receptors</strong> and function as agonists at these sites and are used in the acute treatment of migraine. They are not used for prophylaxis. Although uncommon, the use of triptans has been linked to serious <strong>cardiac complications</strong> such as coronary artery spasm, temporary myocardial ischemia, atrial and ventricular arrhythmias, and myocardial infarction, particularly in individuals with existing coronary artery disease risk factors.</p>\r\n<p><strong>Topiramate (Option C): </strong>An anti-epileptic drug that is also approved for migraine prophylaxis. The more appropriate answer here is propranolol since it is effective for palpitations.</p>\r\n<p><strong>Ergotamine (Option D):</strong> Ergotamines also belong to the group of<strong> triptan</strong> drugs, which are used in the management of acute attacks and not for prophylaxis.</p>",
      "correct_choice_id": 92,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Parenteral iron</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Folic acid</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Filgastrim</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Darbepoietin-alpha</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 60-year-old man with chronic kidney disease presents with complaints of increasing fatigue, dyspnea on exertion, and signs of congestive heart failure. On evaluation, he is found to have anaemia. Which of the following drugs is appropriate for this patient?</span></p>",
      "unique_key": "DT1325308",
      "question_audio": null,
      "question_video": null,
      "map_id": 1325308,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Darbepoetin-alpha </strong>is an erythropoiesis-stimulating agent (ESA) and is indicated for <strong>anaemia of CKD</strong>, especially when the anaemia is symptomatic and haemoglobin levels are low.</p>\r\n<ul>\r\n<li>Anaemia in chronic kidney disease (CKD) is commonly treated with <strong>erythropoiesis-stimulating agents (ESAs)</strong> such as <strong>epoetin alfa</strong> and <strong>darbepoetin alfa, </strong>as it represents a hormone deficiency state.</li>\r\n<li>ESA therapy helps reduce the need for blood transfusions, with dosing tailored to the lowest effective amount.</li>\r\n<li><strong>Subcutaneous administration</strong> is preferred over intravenous because of slower absorption and reduced drug requirement, although intravenous use is common in dialysis patients.</li>\r\n<li>Side effects are more likely when haemoglobin<strong> rises too quickly,</strong> so increases should not exceed 1 g/dL every two weeks, as this is generally considered safe.</li>\r\n</ul>\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>Parenteral iron (Option A): </strong>Used if there is iron deficiency or before starting ESA therapy.</p>\r\n<p>It is not a substitute for erythropoietin in CKD-related anaemia.</p>\r\n<p><strong>Folic acid (Option B): </strong>Useful in megaloblastic anaemia caused by folate deficiency.</p>\r\n<p><strong>Filgastrim (Option C): </strong>Filgrastim is a granulocyte colony-stimulating factor used to manage <strong>chemotherapy-induced myelosuppression </strong>in patients with nonmyeloid cancers, to support recovery in acute myeloid leukaemia after induction or consolidation chemotherapy, as an adjunct following bone marrow transplantation, and in the treatment of <strong>severe chronic neutropenia.</strong></p>",
      "correct_choice_id": 104,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">IL-1</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">IL-4</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">IL-5</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">TNF alpha</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Benralizumab, a monoclonal antibody used to treat asthma, acts against which of the following?</span></p>",
      "unique_key": "DT1325309",
      "question_audio": null,
      "question_video": null,
      "map_id": 1325309,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\r\n<p><strong>Benralizumab </strong>is a humanised monoclonal antibody that targets the<strong> IL-5 receptor alpha</strong> <strong>(IL-5R&alpha;) </strong>on eosinophils and basophils and is used in the treatment of <strong>severe eosinophilic asthma. </strong>and works by inducing antibody-dependent cell-mediated cytotoxicity (ADCC), leading to depletion of eosinophils.</p>\r\n<ul>\r\n<li><strong>Interleukin-5 (IL-5)</strong> plays a central role in eosinophilic inflammation by promoting eosinophil growth, survival, and activation through IL-5 receptor &alpha;, which is mainly found on eosinophils.</li>\r\n<li>Anti-IL-5 and anti-IL-5 receptor monoclonal antibodies suppress eosinophilic inflammation in asthma.</li>\r\n<li>Three key drugs are approved for severe eosinophilic asthma:\r\n<ul>\r\n<li><strong>Mepolizumab</strong>: Antibody against IL-5</li>\r\n<li><strong>Reslizumab</strong>: Antibody against IL-5</li>\r\n<li><strong>Benralizumab</strong>: Antibody against IL-5 receptor alpha</li>\r\n</ul>\r\n</li>\r\n<li>Benralizumab acts by binding IL-5R&alpha; on eosinophils, <strong>inducing apoptosis</strong>, and quickly resolving airway inflammation.</li>\r\n<li>These therapies lower asthma exacerbations with improvements in symptoms, quality of life, and lung function in patients with high eosinophil counts.</li>\r\n</ul>\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>IL-1 (Option A): </strong>Involved in systemic inflammation, targeted by <strong>anakinra</strong>.</p>\r\n<p><strong>IL-4 (Option B): </strong>Plays a role in allergic response and Th2 differentiation; targeted by dupilumab.</p>\r\n<p><strong>TNF-alpha (Option D): </strong>It is a major inflammatory cytokine targeted by drugs like infliximab, adalimumab, and etanercept, which are used in RA and IBD.</p>",
      "correct_choice_id": 113,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Ciprofloxacin</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Fluconazole</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Beta blockers</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Lithium</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient presents with complaints of patches in the oral mucosa, as shown below, with a burning sensation on taking spicy food for the past 6 months. Which of the following drugs can cause this side effect?<br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025091080a7565e-11ce-4c53-9401-1496236620bf.png\"></span></p>",
      "unique_key": "DT1325312",
      "question_audio": null,
      "question_video": null,
      "map_id": 1325312,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation: </strong></p>\r\n<p>The given clinical scenario, along with an image showing lacy reticular lesions, is suggestive of <strong>lichenoid drug eruptions</strong>, which are seen with the use of <strong>beta-blockers.</strong></p>\r\n<ul>\r\n<li><strong>Lichenoid reactions</strong> can be triggered by a wide range of medications, including antihypertensives such as ACE inhibitors, &beta;-blockers, and calcium channel blockers.</li>\r\n<li>Other drugs implicated are diuretics like furosemide, NSAIDs, aspirin, proton pump inhibitors, and statins.</li>\r\n<li><strong>Vaccinations</strong>, such as hepatitis B, and checkpoint inhibitors for cancer therapy are also recognised triggers.</li>\r\n<li>These reactions may present as photodistributed eruptions (lichenoid photoeruptions) or as generalised lesions.</li>\r\n<li>They can appear as plaques, sometimes with <strong>Wickham striae</strong>, papules, or exfoliative erythema. Photolichenoid reactions commonly affect extensor surfaces, including the backs of the hands.</li>\r\n<li>Oral involvement is less common than in idiopathic lichen planus but can occur, especially with <strong>imatinib</strong>, appearing as plaques or erosions; the lower lip is frequently affected. Nails may also be involved and sometimes represent the only site of reaction.</li>\r\n<li>Some reactions are restricted to the oral mucosa, especially with<strong> dental amalgam fillings</strong>, and are linked to metals such as mercury, gold, cobalt, or nickel.</li>\r\n<li>Lichenoid eruptions usually arise within months to years of starting the causative drug and may take equally long to resolve after stopping it.</li>\r\n<li>Histologically, they show inflammation along the <strong>dermo-epidermal junction</strong>, keratinocyte necrosis, and lymphocytic infiltrates.</li>\r\n<li>The histology closely resembles idiopathic lichen planus, though eosinophils may help suggest a drug-induced cause.</li>\r\n<li><strong>Corticosteroids</strong> can be used if the drug cannot be discontinued.</li>\r\n</ul>\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>Ciprofloxacin (Option A): </strong>Ciprofloxacin mainly causes tendinopathy, central nervous system toxicity, and peripheral neuropathy.</p>\r\n<p><strong>Fluconazole (Option B):</strong> Fluconazole is used to treat candidiasis and adverse effects include skin rash, reversible alopecia, and, in some cases, hepatotoxicity.</p>\r\n<p><strong>Lithium (Option D):</strong> Lithium can cause cutaneous lichenoid eruptions and worsen psoriasis, while in the mouth, it more often causes dryness and taste changes; oral lichenoid lesions are rare.</p>",
      "correct_choice_id": 123,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Sodium alginate</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Pantoprazole</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Metoclopramide</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Vonoprazan</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient presents with symptoms of GERD. Which of the following drugs increases the tone of the LES and increases gastric emptying?</span></p>",
      "unique_key": "DT1325313",
      "question_audio": null,
      "question_video": null,
      "map_id": 1325313,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation: </strong></p>\r\n<p><strong>Metoclopramide</strong> is a prokinetic agent that increases lower oesophageal sphincter (LES) tone and enhances gastric emptying, making it effective in managing GERD symptoms.</p>\r\n<p><strong>Dopamine Receptor Antagonists</strong></p>\r\n<ul>\r\n<li><strong>Dopamine </strong>is present in high amounts in the gastrointestinal tract and has inhibitory effects on motility, such as <strong>reducing lower oesophageal sphincter tone</strong> and intragastric pressure.</li>\r\n<li>These effects, mediated by D<sub>2</sub> receptors through inhibition of acetylcholine release, are countered by dopamine receptor antagonists.</li>\r\n<li>These drugs function as <strong>prokinetics </strong>and also relieve nausea and vomiting by blocking dopamine receptors in the brain's chemoreceptor trigger zone.</li>\r\n<li>Examples include metoclopramide and <strong>domperidone</strong>.</li>\r\n</ul>\r\n<p><strong>Metoclopramide:</strong></p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250910b82eaed9-9325-4e21-a444-51489520ebd2.png\">\r\n<p><strong>Explanation of other options:</strong></p>\r\n<p><strong>Sodium alginate (Option A):</strong> Forms a physical barrier (foam/gel) that floats on gastric contents to reduce reflux; does not affect LES tone or gastric motility.</p>\r\n<p><strong>Pantoprazole (Option B):</strong> A proton pump inhibitor (PPI) that reduces acid secretion; does not impact LES tone or gastric emptying.</p>\r\n<p><strong>Vonoprazan (Option D):</strong> A potassium-competitive acid blocker (P-CAB) which suppresses acid secretion but does not affect LES tone or gastric motility.</p>",
      "correct_choice_id": 133,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}